Clinical and economic profile of prucalopride in the treatment of chronic constipation in women

Clinical and economic profile of prucalopride in the treatment of chronic constipation in women

Authors

  • Vincenzo Stanghellini Dipartimento di Medicina Clinica, Policlinico S. Orsola-Malpighi, Università degli Studi di Bologna
  • Mario Eandi Cattedra di Farmacologia Clinica, Facoltà di Medicina e Chirurgia, Università degli Studi di Torino

DOI:

https://doi.org/10.7175/fe.v13i3.271

Keywords:

Prucalopride, Chronic Constipation, Economic profile, Laxatives

Abstract

Chronic constipation is a common disorder, especially in women. Options available for different subgroups of constipation are limited and in most cases unsatisfactory. The most severe forms of chronic constipation often require the use of laxatives in high doses or the use of invasive therapies. The introduction of a new drug, such as prucalopride, active in promoting intestinal transit, can help to improve the therapy of patients with chronic idiopathic constipation who have not found relief from previous treatment with laxatives. In this review, after a brief discussion of pathophysiology and pharmacotherapy of chronic constipation, we evaluate the pharmacological profile, therapeutic and cost of prucalopride, recently authorized in the EU countries and also available in Italy for the treatment of chronic constipation in women who did not benefit from the use of laxatives

Downloads

Published

2012-09-13

How to Cite

Stanghellini, V., & Eandi, M. (2012). Clinical and economic profile of prucalopride in the treatment of chronic constipation in women. Farmeconomia. Health Economics and Therapeutic Pathways, 13(3), 105–120. https://doi.org/10.7175/fe.v13i3.271

Issue

Section

Review (Economic Analysis)

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 2 3 4 5 6 7 8 > >> 
Loading...